Literature DB >> 10525761

Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety.

S D Thakkar1, U Feigen, V F Mautner.   

Abstract

In neurofibromatosis type 1 (NF1) spinal tumours cause neurological symptoms in about 2 % of patients. Among over 1400 patients with NF1 we saw symptomatic spinal tumours in 23 (1.6 %). MRI of the entire spinal canal was obtained in 54 patients aged 5-56 years with NF1. The number, site, morphology and signal characteristics of the spinal tumours were recorded and analysed. There were 24 patients with symptoms such as sensory impairment or paralysis; 30 patients had no neurological deficits. Of the 24 symptomatic patients, 23 (96 %) had spinal tumours, while we saw spinal tumours in 12 (40 %) of the 30 patients without neurological deficits. No spinal segment was preferred in symptomatic or asymptomatic patients. Most intraspinal extramedullary tumours were primarily extradural and intraforaminal. MRI showed intramedullary tumours in 3 patients (6 %), intraspinal extramedullary tumours in 18 (33 %) and intraforaminal tumours in 31 (57 %). Only neurological deficits in patients with NF1 should prompt further diagnostic clarification. In patients with neurological symptoms there may be a multiplicity of masses in the spinal canal, which can lead to difficulties in attaching symptoms to a certain tumour. In patients who do not satisfy the NIH criteria, it can be a helpful observation that spinal tumours in NF1 are primarily intraforaminal, extending into the spinal canal, while in NF2 they are mostly intraspinal intradural tumours.

Entities:  

Mesh:

Year:  1999        PMID: 10525761     DOI: 10.1007/s002340050814

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  40 in total

1.  The value of screening tests in children with neurofibromatosis type 1 (NF1).

Authors:  Eloïse Baudou; Yves Chaix
Journal:  Childs Nerv Syst       Date:  2020-06-10       Impact factor: 1.475

2.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

Authors:  V F Mautner; M Hartmann; L Kluwe; R E Friedrich; C Fünsterer
Journal:  Neuroradiology       Date:  2006-01-24       Impact factor: 2.804

Review 3.  Intradural spinal tumors: current classification and MRI features.

Authors:  Kasim Abul-Kasim; Majda M Thurnher; Paul McKeever; Pia C Sundgren
Journal:  Neuroradiology       Date:  2007-12-15       Impact factor: 2.804

Review 4.  Spinal deformity in neurofibromatosis type-1: diagnosis and treatment.

Authors:  Athanasios I Tsirikos; Asif Saifuddin; M Hilali Noordeen
Journal:  Eur Spine J       Date:  2005-02-15       Impact factor: 3.134

5.  Extensive plexiform neurofibroma in a premature neonate.

Authors:  Aditya Joshi; Moira Lancelot; Nandita R Bhattacharjee; Sruthi Polavarapu; Efstathios Beltaos; Babatunde Sobowale
Journal:  Clin Med Res       Date:  2014-11-07

6.  Craniovertebral junction cord compression due to neurofibroma.

Authors:  Omprakash Prasad; Nandakishore Bompelli; Rakesh Reddy; Pavan Reddy; Anirudda Deshpande
Journal:  BMJ Case Rep       Date:  2018-06-27

7.  Simultaneous Moyamoya disease and cervical spinal cord low-grade astrocytoma in a child with neurofibromatosis type 1.

Authors:  Jeffrey J Gold; Chris E Dory; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2013-05-08

8.  Ganglioglioma of conus medullaris in a patient of neurofibromatosis type 1: A novel association?

Authors:  Ilangovan Vijay Sundar; Manish Jaiswal; Devendra Purohit; R S Mittal
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec

9.  Spinal cord ependymoma associated with neurofibromatosis 1 : case report and review of the literature.

Authors:  Hongwei Cheng; Ming Shan; Chunguo Feng; Xiaojie Wang
Journal:  J Korean Neurosurg Soc       Date:  2014-01-31

10.  Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofibromatosis and a Factor V Leiden Mutation.

Authors:  José L Gálvez; Carlos L Errando; Silvia Serrano; Marga Martín-Ayuso; José M Valverde-Mantecón
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.